This volume will address an important emergent area within the field of
immunomics: the discovery of antigens and adjuvants within the context
of reverse vaccinology. Conventional approaches to vaccine design and
development requires pathogens to be cultivated in the laboratory and
the immunogenic molecules within them to be identifiable. Conventional
vaccinology is no longer universally successful, particularly for
recalcitrant pathogens. By using genomic information we can study
vaccine development in silico: 'reverse vaccinology', can identify
candidate subunits vaccines by identifying antigenic proteins and by
using equally rational approaches to identify novel immune
response-enhancing adjuvants.